Sclerosing Cholangitis

Sclerosing cholangitis is a long-term condition that affects the bile ducts, which are tubes that carry bile from the liver to the gallbladder. Over time, these ducts become scarred and thickened, which can block the flow of bile. This can cause symptoms like itching, jaundice, and abdominal pain. It's a chronic disease, meaning it lasts a long time.

Condition

What people with Sclerosing Cholangitis report

Every report comes from a Lived member, sent anonymously.

Have you had Liver Transplant for Sclerosing Cholangitis?

NameHow it went

About Sclerosing Cholangitis

What It Is

Sclerosing cholangitis is a long-term disease in which the bile ducts become inflamed, scarred and narrowed. Bile ducts are the tubes that carry bile, a digestive fluid made by the liver, into the intestine. When scarring narrows them, bile backs up in the liver (a state called cholestasis), and over years this can damage the liver and lead to cirrhosis, meaning widespread scarring of the liver itself. The most common form, primary sclerosing cholangitis (PSC), has no single identifiable cause and affects ducts both inside and outside the liver. About half of people have no symptoms when it is found, often because a routine blood test showed abnormal liver results. Others notice tiredness, itching, discomfort in the upper right abdomen, or yellowing of the skin and eyes (jaundice). The condition matters not only because of the liver but because it raises the risk of bile duct and colon cancer, which shapes much of the ongoing care. The same pattern of duct scarring can also have a known cause, such as stones lodged in the bile duct, injury after surgery or certain infections. This is called secondary sclerosing cholangitis and is managed largely by addressing that cause.

Causes & Risk Factors

The cause of primary sclerosing cholangitis is not known. Researchers think it arises when the immune system reacts abnormally in people with an inherited susceptibility, possibly influenced by signals from the gut. Several gene regions, especially ones involved in immune function, are linked to it, and it is more common in brothers and sisters of affected people, but it is not passed down in a simple, predictable way. The strongest association is with inflammatory bowel disease (IBD). Most people with PSC, roughly 60 to 80 percent, also have IBD, most often ulcerative colitis and less often Crohn's disease. The reverse is uncommon: only about 2 percent of people with IBD develop PSC. The bowel disease can be mild or even unnoticed, so it is often found only when someone with PSC has a colonoscopy. PSC is rare, affecting roughly 13 in 100,000 people. Men are affected about twice as often as women, and the average age at diagnosis is around 40, although children can have it too.

How It's Diagnosed

Suspicion usually starts with liver blood tests showing a cholestatic pattern, meaning a raised alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). These are enzymes that rise when bile does not flow freely. They point to a bile problem but do not identify which one, and about a quarter of people with PSC have normal results at some point. The key test is magnetic resonance cholangiopancreatography (MRCP), a type of magnetic resonance imaging (MRI) scan that shows the bile ducts without any instruments entering the body. In PSC it typically shows ducts with a beaded look, alternating narrowed and widened segments. Endoscopic retrograde cholangiopancreatography (ERCP), in which a flexible scope is passed through the mouth to inject dye into the ducts, is now used mainly when a narrowing needs to be opened or sampled, because it carries a risk of complications such as pancreatitis. PSC is diagnosed only after other explanations are ruled out. These include stones in the bile duct, bile duct cancer and IgG4-related sclerosing cholangitis, a look-alike marked by high levels of an antibody called IgG4 that, unlike PSC, usually improves with steroids. A liver biopsy is not routinely needed, but it helps when imaging is normal despite suggestive blood tests (small-duct PSC, a milder variant) or when autoimmune hepatitis may also be present. Because of the strong link with bowel disease, a colonoscopy is part of the initial assessment even without bowel symptoms. Many clinics also measure liver stiffness with an ultrasound-based scan such as FibroScan to estimate how much scarring is present.

Treatment Options

No medicine has yet been shown to slow primary sclerosing cholangitis. Treatment therefore aims to relieve symptoms, treat complications, catch cancer early, and plan for a liver transplant if the liver begins to fail. Ursodiol (ursodeoxycholic acid), a bile acid medicine, is sometimes prescribed at standard doses because it can improve liver blood tests. Whether it changes the long-term course is unproven, and specialists disagree about using it. High doses caused serious harm in a clinical trial and are avoided. Steroids and other immune-suppressing drugs have not shown consistent benefit in PSC alone; the exception is when autoimmune hepatitis is also present, in which case it is treated as autoimmune hepatitis. Itching can be persistent and wearing. Cholestyramine, a powder that binds bile acids in the gut, is a common first option, and other medicines can be tried if it does not help. Because poor bile flow limits absorption of vitamins A, D, E and K, people may need supplements, and bone density is checked because of the risk of thinning bones. When a significant narrowing causes jaundice, itching or infection, a gastroenterologist can stretch it with a balloon during ERCP, sometimes placing a short-term stent, and take samples to look for cancer. This can relieve symptoms and improve blood tests, but it treats a single blockage rather than the underlying disease. Bile duct infections are treated with antibiotics, often followed by ERCP to clear the blockage. Liver transplantation is the only treatment that replaces the damaged liver. It is considered for advanced liver disease, repeated bile duct infections that cannot be controlled, severe itching that does not respond to treatment, and selected early bile duct cancers. About 80 to 85 percent of people are alive five years after transplant, although PSC returns in the new liver in roughly 20 to 30 percent, usually slowly. Several newer drugs are being tested in clinical trials but are not yet established.

What to Expect

The course of PSC varies widely. Some people stay well for many years with only abnormal blood tests, while others develop symptoms and complications sooner. Over the course of the disease, roughly 40 to 50 percent of people develop serious liver complications or need to be considered for a transplant. Small-duct PSC generally has a better outlook than the more common form. Ongoing care centers on regular monitoring with a liver specialist. Blood tests track liver function, and yearly imaging, usually MRI with MRCP, looks for new narrowing and for bile duct and gallbladder cancer. Bile duct cancer (cholangiocarcinoma) develops in an estimated 5 to 15 percent of people with PSC, and many of these cases appear in the first few years after diagnosis, which is why follow-up starts right away. People who have developed cirrhosis are also checked for liver cancer with an ultrasound every six months. Because PSC with bowel disease raises the risk of colon cancer, often at a younger age, guidelines recommend a colonoscopy at diagnosis and then every one to two years for people with IBD, or about every five years for those without it. Removing the colon for ulcerative colitis does not slow the liver disease. Fatigue and itching can affect sleep, work and mood more than test results suggest, and they are worth raising at every visit. Day to day, most people live normally between appointments. Keeping alcohol low and reviewing new medicines and supplements with the care team help protect the liver.

When to Seek Help

See a clinician if liver blood tests are repeatedly abnormal, or if you have IBD and develop ongoing itching, unexplained tiredness or yellowing of the skin or eyes. If you already have PSC, tell your care team about new or worsening itching, weight loss or changes in your bowel symptoms. Fever with chills, especially together with pain in the upper right abdomen or new or deeper jaundice, can mean a bile duct infection (bacterial cholangitis). Contact your liver team right away, because it needs prompt antibiotics and sometimes a procedure to drain the duct. If that fever comes with confusion, fainting or feeling severely unwell, go to an emergency department. For people with cirrhosis, vomiting blood or passing black, tarry stools can mean bleeding from enlarged veins in the esophagus or stomach. Call 911.

Questions to Ask Your Doctor

  1. 1.Do I have the typical large-duct form, small-duct PSC, or another kind of sclerosing cholangitis, and how does that change my outlook?
  2. 2.What does my monitoring schedule look like for imaging, blood tests and colonoscopy, and who coordinates it?
  3. 3.Is ursodiol or a clinical trial worth considering in my situation, and what would we expect it to achieve?
  4. 4.What can we do about my itching and fatigue if the first treatment does not help?
  5. 5.At what point would we talk about a liver transplant evaluation?

Last reviewed • Oct 2026

Educational content, not medical advice.